Saturday, June 24, 2017

Promising new drug for relapsed AML


Image shows increasing white blood cells in leukemia
Illustration by Scientific Animations
Image used under Creative Commons license via
Wikipedia
CANCER DIGEST – June 24, 2017 – Researchers have found a drug that inhibits a particular mutation in a deadly form of acute myeloid leukemia (AML) with promise of producing longer survival.
The sub-type of AML has a mutation in a gene called FLT3, found in about 30 percent of patients’ leukemia cells.

Saturday, June 17, 2017

Drug Improves overall survival in older patients with thyroid cancer

Illustration courtesy of Cancer Research UK
CANCER DIGEST – June 17, 2017 – A drug used to treat thyroid cancer that is resistant to standard therapy has been shown to increase survival in older patients, according to researchers.

Most cases of differentiated thyroid cancer (DTC) are 
successfully treated with radioiodine therapy. The thyroid absorbs nearly all of the iodine in the human body, consequently, patients with DTC are given radioactive iodine, which concentrates in thyroid cancer cells, killing them with little effect on the rest of the body. The treatment can be curative, but about 15 percent of DTC patients have cancers that are resistant to the therapy.

Saturday, June 10, 2017

No survival benefit from surgery for advanced breast cancer

CANCER DIGEST – June 10, 2017 – A new Austrian study could change treatment for women diagnosed with advanced stage breast cancer that has spread throughout the body.

Based on several analyses of past studies, current therapy starts with surgery to remove the main breast tumors followed by chemotherapy to try to kill the remaining tumors dispersed throughout the body, or hormone therapy to block or prevent hormones from feeding further tumor growth, called hormone therapy.

Saturday, May 27, 2017

Where your fat is carried can predict cancer risk



CANCER DIGEST – May 27, 2017 – Scientists have found that carrying fat around your middle could be as good an indicator of cancer risk as body mass index (BMI), according to research published in the British Journal of Cancer.

This is the first study comparing adult body measurements in such a standardized way for obesity-related cancers. The study combined data from more than 43,000 participants who had been followed for an average of 12 years and more than 1,600 people were diagnosed with an obesity-related cancer.

Wednesday, May 17, 2017

Nanovaccine shows promise for variety of cancers

Laser light is scattered by nanoparticles
in a solution of the UTSW-developed
nanovaccine. – Photo courtesy UTSW
CANCER DIGEST – May 17, 2017 – In another approach using nanotechnology to boost the body’s immune system to attack cancer, researchers at the University of Texas Southwestern’s Simmons Cancer Center, have shown in a proof-of-concept study that a nanovaccine extended survival in mouse models of a variety of cancers.

The study published online in the journal Nature Nanotechnology showed effective anti-tumor action in tumor models of melanoma, colorectal cancer, and HPV-related cancers of the cervix, head, neck and anogenital cancers.